Several pharmacological inhibitors for the NLRP3 inflammasome (MCC950, N-acetyl cysteine or acetyl-L-carnitine) recover mitophagic flux, at least partially, and inhibit inflammasome activation and pyroptosis, thus being helpful in improving the NASH model [159]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.